Adomeglivant is an investigational small molecule being studied primarily for its potential in treating metabolic disorders, particularly type 2 diabetes. It functions as a glucokinase activator, enhancing the activity of glucokinase—a key enzyme involved in glucose metabolism. By stimulating glucokinase in pancreatic beta cells and liver cells, Adomeglivant helps improve glucose sensing and insulin release, while promoting glucose uptake and utilization in the liver. This dual action helps lower blood glucose levels in a glucose-dependent manner, reducing the risk of hypoglycemia. Its targeted mechanism makes it a promising candidate for improving glycemic control without the side effects commonly associated with other antidiabetic agents. Clinical development is ongoing to evaluate its efficacy, safety, and long-term benefits in diabetic and prediabetic populations.